



Published on *Puma Biotechnology Investor Center* (<https://investor.pumabiotechnology.com>) on 10/26/17 1:20 pm PDT

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Release Date:

Thursday, October 26, 2017 1:20 pm PDT

Terms:**Dateline City:**

LOS ANGELES

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, November 9, 2017, following release of its third quarter 2017 financial results.

The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least ten minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at <http://www.pumabiotechnology.com>. A replay of the call will be available approximately one hour after completion of the call and will be archived on the company's website for 90 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates — PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. NERLYNX™ (neratinib) is approved for commercial use by prescription in the United States as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and is marketed as NERLYNX. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the commercialization of NERLYNX and the continued development of its other advanced drug candidates directed at the treatment of HER2-positive breast cancer. The Company believes that NERLYNX has clinical application in the potential treatment of several other cancers that over-express or have a mutation in HER2.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

Forward-Looking Statements

This press release and the webcast of the presentation contain forward-looking statements, including statements regarding the benefits of NERLYNX™ and neratinib, the Company's clinical trials and the announcement of data relative to those trials. All forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Language:

English

Contact:

Puma Biotechnology, Inc.
Alan H. Auerbach or Mariann Ohanesian, +1-424-248-6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
or

Russo Partners
David Schull or Amiad Finkelthal, +1-212-845-4200
david.schull@russopartnersllc.com
amiad.finkelthal@russopartnersllc.com

Ticker Slug:

Ticker: PBYI

Exchange: NASDAQ
ISIN:
US74587V1070

Source URL: <https://investor.pumabiotechnology.com/press-release/puma-biotechnology-host-conference-call-discuss-third-quarter-financial-results>